Jun 27, 2024, 09:10
The promise of immuno-oncology in the neoadjuvant setting – ESMO
The European Society for Medical Oncology (ESMO) shared on LinkedIn:
“The promise of immuno-oncology in the neoadjuvant setting.
Recent studies highlight novel pre-operative therapeutic options that are showing promise.
While there are still challenges to address, early clinical trials in the neoadjuvant setting could pave the way for practice-changing strategies to help a larger number of people with cancer.
To learn more about this topic, read the ESMO Daily Reporter new column by Elena Garralda Cabanas.”
Source: ESMO/LinkedIn
Jul 1, 2024, 19:16